VentriLinks offers an AI‑driven agent that automates biotech diligence, delivering investor‑grade evaluations of startups, assets, IP, and therapeutic programs. By aggregating millions of abstracts, publications, trial records, and curated databases, the platform provides evidence‑backed competitive landscapes, freedom‑to‑operate analyses, and market sizing, with each claim traceable to its original source.
Funding
Funding not disclosed
Founders
Product
Problem
Biotech investors and corporate development teams must manually gather and analyze vast amounts of scientific literature, clinical trial data, patent filings, and market information to assess startups, assets, and therapeutic programs. This process is time‑intensive, prone to gaps, and often lacks a transparent evidence trail, leading to delayed or sub‑optimal investment decisions.
Solution
VentriLinks offers an AI‑driven diligence platform that automates the synthesis of millions of abstracts, publications, trial records, patents, and curated databases into structured, evidence‑backed intelligence. Users define a case, and the system generates competitive landscapes, freedom‑to‑operate analyses, clinical risk assessments, market sizing, and investment memos with source‑traced provenance for every claim. The platform presents results through a web interface that allows rapid refinement and iteration, reducing the time to a first‑draft memo from weeks to a few hours. By linking drugs, targets, trials, companies, and evidence in a unified knowledge graph, VentriLinks ensures comprehensive coverage across global registries, patent offices, and preprint servers. The service is billed based on token consumption, aligning cost directly with the amount of AI processing required for each diligence run.
Target Audience
Primary customers are biotech investors, venture capital firms, and corporate development or R&D teams at pharmaceutical companies that need fast, comprehensive due‑diligence on therapeutic assets, targets, and emerging companies.
Features
- Unified knowledge graph covering 1.6 M entities (drugs, targets, trials, companies) with over 1.3 M evidence artifacts, each fact linked to its source
- AI agent that generates investor‑grade reports for competitive landscapes, FTO, clinical trial risk, market sizing, and investment memos
- Structured output with provenance metadata, enabling traceability of every claim to original abstracts, trial records, or patent filings
- Token‑based usage model with subscription tiers (Analyst $500/mo, Enterprise $1,000/mo) and pay‑as‑you‑go option, billing for actual model input/output and cache reads
- Rapid workflow: specify case, synthesize data, refine results, delivering first‑draft reports in ~4 hours
- Integration of identifiers from major databases (ChEMBL, DrugBank, PubChem, Open Targets, SEC filings) for seamless cross‑referencing
- Scalable throughput with priority processing for enterprise customers and configurable spending caps to control costs